{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Acute Respiratory Distress Syndrome",
            "NStudiesAvail": 430108,
            "NStudiesFound": 56,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 56,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2016-01184"
                        ],
                        "SecondaryIdDomain": [
                              "NCI CTRP"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Clinical improvement defined as decreased mechanical ventilation after the mesenchymal stem cell (MSC) infusion.",
                              "An improvement in PF or S/F ratio defined as decreased mechanical ventilatory requirement."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)",
                              "Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 7 days and 30 days",
                              "Baseline, 7 days and 30 days"
                        ],
                        "SeeAlsoLinkLabel": [
                              "University of Texas MD Anderson Cancer Center Website"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02804945"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [
                              "December 18, 2015"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "May 2, 2017"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "1U01HL108713-01"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/1U01HL108713-01"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "The number of participants with a severe adverse event during the study was assessed.",
                              "Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.",
                              "Days on vasopressor to day 28 after study enrollment",
                              "The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.",
                              "The number of patients expired at hospital discharge."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of Severe Adverse Events (SAEs)",
                              "Ventilator Free Days at Study Day 28",
                              "Duration of Vasopressor Use (Days)",
                              "ICU Free Days to Day 28",
                              "Hospital Survival to Day 60",
                              "Mortality at Hospital Discharge"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first.",
                              "time of initiating unassisted breathing to day 28",
                              "28 days",
                              "28 days after study enrollment",
                              "60 days after randomization",
                              "From study enrollment to Hospital discharge"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Non-systematic Assessment",
                              "Non-systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT01775774"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Safety evaluation of WJ-MSC describing and comparing incidence, type and severity of adverse events in both groups.",
                              "Evaluation of the effect of WJ-MSC in the time of mechanical ventilation compared between the two groups, as prolonged mechanical ventilation days are associated with higher complication risks as pneumonia, tracheostomy and death.",
                              "Evaluation of the effect of WJ-MSC in the time of hospitalization between the two groups as a measure of efficacy.",
                              "Evaluation of the effect of WJ-MSC in the time of oxygen needs compared between the two groups as a measure of efficacy.",
                              "\"Sequential Organ Failure Assessment\" (SOFA) score is a tool used to determine the beginning and evolution of multiorgan failure, ranging from 0 to 24, being 24 the worst scenario. It has been proven useful as an outcome predictor of mortality and ICU stay. The result is the addition of the evaluation of each organ or system. Effect of WJ-MSC in the SOFA score will be compared between the two groups.",
                              "Murray score is a tool used to classify lung injury. 0 = no lung injury, 0.1-2.5, mild to moderate lund injury, >2.5 Acute respiratory distress syndrome.\n\nThe effect of WJ-MSC in the Murray score will be compared between the two groups.",
                              "APACHE II is a prognostic score based on 12 different items obtained in the first 24 hours of ICU admission. Its mainly used as a single measure, but some authors have used and described prediction usefulness with repeated measures. It ranges from 0 to 71 points. Higher scores are related to higher ICU mortality.\n\nThe effect of WJ-MSC in the APACHE II score will compared between the two groups.",
                              "Evaluation of the effect of WJ-MSC in lymphocyte count measured in absolute number/mm3.\n\nThese laboratory measures have been associated with COVID 19 severity.",
                              "Evaluation of the effect of WJ-MSC in C reactive protein concentration between the two groups, measured in mg/dl.\n\nHighest levels have been associated with COVID 19 severity and inflammation.",
                              "Evaluation of the effect of WJ-MSC in D dimer between the two groups, measured in micrograms Highest levels have been associated with COVID 19 severity and thromboembolic complications.",
                              "Evaluation of the effect of WJ-MSC in ferritin compared between the two groups, measured in nanograms/ml.\n\nThese laboratory measures have been associated with COVID 19 infection and severity.",
                              "Evaluation of the effect of WJ-MSC in LDH compared between the two groups, measured in units/liter.\n\nThese laboratory measures have been associated with COVID 19 infection and severity.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation.The effect of WJ-MSC in IL-6 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 8 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 10 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in TNF alpha will be compared between the two groups. It will be measured in nanograms/ml."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients with treatment related adverse events",
                              "Difference in days of mechanical ventilation between groups",
                              "Median reduction of days of hospitalization",
                              "Median reduction of days of oxygen needs",
                              "Difference between \"Sequential Organ Failure Assessment\" score between groups",
                              "Difference between median Murray score between groups",
                              "Difference in APACHE II score between groups",
                              "Difference in lymphocyte count between groups",
                              "Changes in C reactive protein concentration between groups",
                              "Changes in D dimer concentration",
                              "Changes in ferritin concentration",
                              "Changes in lactate dehydrogenase concentration",
                              "Impact on interleukin 6 concentrations between groups.",
                              "Impact on interleukin 8 concentrations between groups.",
                              "Impact on interleukin 10 concentrations between groups.",
                              "Impact on tumor necrosis factor alpha concentrations between groups."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months.",
                              "From ICU admission to 180 days.",
                              "From hospital admission to 180 days.",
                              "From hospital admission to 180 days.",
                              "Baseline to 7 days",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "Baseline to 7 days."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Days in hospital ICU free days at day 28 Ventilator free days at day 28"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Hospital indices by treatment group"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From admission to discharge"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01902082"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The days without invasive ventilator support(at least 2 consecutive calendar days) in 28 days.\n\nIf the ventilator weaned multiple times, VFDs is the sum of the days without ventilator support.\n\nIf any of following occurring in 28 days, VFDs equals 0:\n\nThe patient dies in 28 days;\nVentilator never be weaned;\nCensored case with ventilator never being weaned.",
                              "The oxygenation index(OI)=partial pressure of oxygen in arterial blood(PaO2) divide inspiration fraction of oxygen(FiO2). OI is measured at day0, day1,day3,day7.",
                              "Murray lung injury scores (LIS) consist of the following 4 parts:\n\nA.Hypoxemia (PaO2/FiO2\u2265300, 225-299,175-224,100-174,<100, assigned 0,1,2,3,4 scores respectively); B.PEEP (cmH2O) (\u22645,6-8,9-11,11-14,\u226515, assigned 0,1,2,3,4 scores respectively) ; C.Compliance (ml/cmH2O)(\u226580,60-79,40-59,20-39,\u226419, assigned 0,1,2,3,4 scores respectively); D.Quadrants infiltrated in Chest X-Ray(CXR) (0,1,2,3,4, assigned 0,1,2,3,4 scores respectively).\n\nThe total LIS score is obtained by dividing the total sum of points by the number of criteria present. For example, if only 3 criteria are answered to, the total sum is divided by 3 to reveal the final score.\n\nThe LIS score ranges between 0 and 4, with scores closer to 4 indicating severe acute lung injury.",
                              "Monitored by ventilator and recorded per hour, obtain the average value of the day. unit-cmH20",
                              "Monitored by ventilator in one inspiration pause, measured 4 times a day. Record the average value of the day. unit-cmH20",
                              "Calculate the driving pressure by Pplat minus PEEP, measured 4 times a day. Record the average value of the day. unit-cmH20",
                              "Calculate the static compliance by the following formula:\n\nstatic compliance=tidal volume/(Pplat-PEEP), unit-ml/cmH2O"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Ventilation free days(VFDs)",
                              "Oxygenation index(OI) changes",
                              "Lung injury score(LIS)",
                              "Positive end expiratory pressure(PEEP)",
                              "Plateau pressure(Pplat)",
                              "Driving pressure",
                              "Static compliance"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From the day of UCMSCs use(day 0) to day 28",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, day0,1,3,7",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, each day",
                              "From day 0 to day 7, each day"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To assess the effect of the proposed treatment on the total Leukocytes",
                              "To assess the effect of the proposed treatment on absolute lymphocytes",
                              "To assess the effect of the proposed treatment on total platelets",
                              "To assess the effect of the proposed treatment on serum fibrinogen",
                              "To assess the effect of the proposed treatment on procalcitonin",
                              "To assess the effect of the proposed treatment on ferritin",
                              "To assess the effect of the proposed treatment on D-dimer",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of C-reactive protein",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of TNFa in plasma.",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL10 in plasma.",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL1 in plasma.",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL6 in plasma.",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL17 in plasma",
                              "To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of VEGF in plasma",
                              "Assess the radiological evolution of the proposed treatment through simple chest CT",
                              "Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: regulatory T cells",
                              "Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: dendritic cells",
                              "Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: CD4 + T",
                              "Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: CD8 + T",
                              "Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: NK cells",
                              "Evaluate the safety of the proposed treatment (allergic reactions and / or infection)",
                              "To assess the negativization of the SARS-Cov2 PCR RNA detection test"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "General biochemical changes in Leukocytes",
                              "General biochemical changes on lymphocytes",
                              "General biochemical changes on platelets",
                              "General biochemical changes on fibrinogen",
                              "General biochemical changes on pocalcitonin",
                              "General biochemical changes on ferritin",
                              "General biochemical changes on D-dimer",
                              "Changes on inflammatory C-reactive protein",
                              "Cahnges on Inflammatory cytokine TNFa",
                              "Changes on Inflammatory cytokine IL10",
                              "Changes on Inflammatory cytokine IL1",
                              "Changes on Inflammatory cytokine IL6",
                              "Changes on Inflammatory cytokine IL 17",
                              "Changes on VEGF",
                              "Radiological Changes",
                              "Immunological changes on T cell",
                              "Immunological changes on Dendritic cells",
                              "Immunological changes on CD4+ T",
                              "Immunological changes on CD8+ T",
                              "Immunological changes on NK cell",
                              "Adverse events",
                              "RNA detection by SARS-Cov2 PCR"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks",
                              "Three weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04416139"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2019-002688-89"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "SOFA index from 0 to 4 where lower scores represent improvement",
                              "Murray scale from 0 to 4 where lower scores represent improvement"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040",
                              "Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040",
                              "Mechanical ventilation-free days 28 days after the administration of HCR040",
                              "Percent mortality 28 days after the administration of HCR040",
                              "Daily pulmonary mechanics values (Ppl, DP, CRS)",
                              "Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040",
                              "Vasopressor-free days 28 days after the administration of HCR040",
                              "ICU-free days 28 days after the administration of HCR040"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "One year",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2020-06741",
                              "2020-0365"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "M D Anderson Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Will be estimated and reported with 95% confidence intervals.",
                              "Will be estimated and reported with 95% confidence intervals.",
                              "Will be estimated and reported with 95% confidence intervals.",
                              "Will be estimated and reported with 95% confidence intervals.",
                              "Will be estimated and reported with 95% confidence intervals.",
                              "The effect of MSCs on clinical parameters will be assessed. Continuous clinical parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.",
                              "The effect of MSCs on oxygenation parameters will be assessed. Continuous oxygenation parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.",
                              "The effect of MSCs on respiratory parameters will be assessed. Continuous respiratory parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.",
                              "The effect of MSCs on laboratory markers will be assessed. Continuous laboratory parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.",
                              "All grades of infusion-related adverse events will be summarized by grade and type."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)",
                              "Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)",
                              "Overall survival rate (Phase I)",
                              "Survival rate in patients who present intubated on ventilator support (Phase I)",
                              "Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)",
                              "Clinical parameters (Phase I)",
                              "Oxygenation parameters (Phase I)",
                              "Respiratory parameters (Phase I)",
                              "Laboratory markers (Phase I)",
                              "Hospitalization stay (Phase I)",
                              "Intensive care unit stay (Phase I)",
                              "Incidence of infusion-related adverse events (Phase I)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "At day 30 post MSC infusion",
                              "At day 30 post MSC infusion",
                              "At day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion",
                              "Up to day 30 post MSC infusion"
                        ],
                        "SeeAlsoLinkLabel": [
                              "M D Anderson Cancer Center"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04565665"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "IRCT20200217046526N2"
                        ],
                        "SecondaryIdDomain": [
                              "Iranian Registry of Clinical Trials (IRCT)"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Number of days",
                              "Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing",
                              "increase in PaO2/FiO2 ratio from baseline to day 7",
                              "Biochemical examination"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Intensive care unit-free days",
                              "Clinical symptoms",
                              "Respiratory efficacy",
                              "Biomarkers concentrations in plasma"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to day 8",
                              "From baseline to day 14",
                              "From baseline to day 7",
                              "At baseline, 7, 14, 28 days after the first intervention"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04366063"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The minimum value is 0 and the maximum are 16. Higher scores mean a worse outcome.",
                              "oxygen index: the ratio of alveolar oxygen partial pressure to fraction of inspired oxygen",
                              "The minimum value is 0 and the maximum are 48. Higher scores mean a worse outcome.",
                              "The minimum value is 0 and the maximum are 24. Higher scores mean a worse outcome.",
                              "The number of days the survivor was in ICU"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Murray lung injury score",
                              "PaO2/FiO2",
                              "SOFA score",
                              "Apach\u2161 score",
                              "The number of days the survivor was in ICU"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60",
                              "baseline and Day 3, Day7, Day14, Day28, Day60",
                              "baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60",
                              "baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60",
                              "up to 60 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04602104"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "All-cause mortality rate at Days 60 and 90",
                              "Number of ventilator-free days through Day 28",
                              "Number of ICU days through Day 28",
                              "Clinical status as assessed using the Ordinal Scale for Clinical Improvement (0-8 scale, where lower score means better outcome)",
                              "Change in oxygenation at Days 2, 4, 6, 14, and 28 as measured using PaO2:FiO2 ratio."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "All-cause mortality rate at Days 60 and 90",
                              "Number of ventilator-free days through Day 28",
                              "Number of ICU days through Day 28",
                              "Clinical status at Day 28",
                              "Change in oxygenation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Day 60 and Day 90",
                              "Baseline through Day 28",
                              "Baseline through Day 28",
                              "Baseline to Day 28",
                              "Baseline to Day 2, Day 4, Day 6, Day 14, Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in mmHg of Arterial partial pressure of oxygen / Fraction of inspiration O2 (PaO2/FiO2) in all participants",
                              "Changes in percentage of participants with reduction in bilateral ground-glass opacities",
                              "Changes in percentage of participants with reduction of pneumonia bilateral infiltration",
                              "Number of participants with a reduction in Lactate dehydrogenase (mg/dL)",
                              "Number of participants with a reduction in C-reactive protein (mg/dL)",
                              "Number of participants with a reduction in D-dimer (mg/dL)",
                              "Number of participants with a reduction in Ferritine (mg/dL)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Oxygen pressure in inspiration",
                              "ground-glass opacity",
                              "Pneumonia infiltration",
                              "Lactate dehydrogenase",
                              "C-reactive protein",
                              "D-dimer",
                              "Ferritine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, and at days 2, 4 and 14 post-treatment",
                              "Baseline, and at day 14 post-treatment",
                              "Baseline, and at day 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The evolution of the PaO2/FiO2 ratio between Day 0 (or Day 1) and Day 14 of treatment with MSC-GW or placebo is a secondary endpoint.",
                              "The effect of WJ-MSC on respiratory assistance is evaluated by the proportion of days without invasive respiratory assistance during the hospital stay and maximum on Day 28 (number of days without invasive respiratory assistance / number of hospital days fixed at day 28)",
                              "Difference in sequential organ failure assessment score (SOFA score), grading 0 (best) to 4 (worst), between Day 5-Day 0 and D14-Day 0",
                              "number of days without extra-renal treatment / number of hospital days fixed at day 28",
                              "number of days without vasopressor support",
                              "The duration of stay in intensive care unit",
                              "Cause of death during the stay in intensive care unit and during the hospital stay, on Day 28 and Day 90",
                              "respiratory morbidity on Day 90",
                              "The evolution of the viral load is evaluated by RT PCR SARS-Cov-2 monitoring on a nasopharyngeal swab (or any other sample) at diagnosis, at Day 7, Day 14, Day 21, Day 28 or on the last day of hospitalisation",
                              "- The anti-HLA antibody rate measured on Day 0 (before initiating treatment), on Day 28 and on Day 90",
                              "The occurrence of immediate hypersensitivity reactions (chills, hyperthermia associated with hypotension) within 4 to 6 hours of the WJ MSC or placebo infusion.",
                              "The thromboembolic risks monitored biologically by routinely daily monitoring of hemostasis (TP, TCA, Fibrinogen, D-dimers)",
                              "daily monitoring of transthoracic echocardiography",
                              "blood cultures in case of T\u00b0 > 38,5\u00b0C"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "respiratory function evolution",
                              "respiratory assistance",
                              "organ failures 1",
                              "organ failures 2",
                              "organ failures 3",
                              "duration of intensive care",
                              "Cause of death",
                              "respiratory morbidity (TDM, functional respiratory measures)",
                              "viral load",
                              "Anti-HLA antibody rate",
                              "immediate hypersensitivity reactions",
                              "thromboembolic adverse events 1",
                              "thromboembolic adverse events 2",
                              "infectious adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "between Day 0 (or Day 1) and Day 14 of treatment",
                              "between day 0 (or 1) and day 28 (or last day of hospitalization if before day 28)",
                              "Day 0 to day 14",
                              "day 0 to day 28",
                              "day 0 to day 28",
                              "day 0 to 90",
                              "day 0 to 90",
                              "day 90",
                              "day 0 to day 28 (or last day of hospitalization if before day 28)",
                              "day 0 to day 90",
                              "day 0, day 3, day 5 (+/- 1day)",
                              "day 0 to day 14",
                              "day 0 to day 14",
                              "day 0 to day 14"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Improvement in mortality status.",
                              "Improvement in clinical function as assessed by Ventilator Free Days (VFD).",
                              "Improvement in clinical function as assessed by change in Oxygenation Index (OI).",
                              "Improvement in clinical function as assessed by change in Lung Injury Score (LIS), 0-16 points, severity increasing with higher points.",
                              "Improvement in clinical function as assessed by change in positive end-expiratory pressure (PEEP).",
                              "Improvement in clinical function as assessed by change in Lung Static Compliance",
                              "Improvement in clinical function as assessed by change in acute physiology and chronic health evaluation score (APACHE II), higher scores correspond to more severe disease and a higher risk of death."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in mortality status",
                              "Ventilator Free Days (VFD)",
                              "Change in Oxygenation Index (OI)",
                              "Change in Lung Injury Score (LIS)",
                              "Change in positive end-expiratory pressure (PEEP)",
                              "Change in Lung Static Compliance",
                              "Change in acute physiology and chronic health evaluation score (APACHE II)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "15 months from the day of administration.",
                              "28 days from the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days or discharge from ICU after the day of administration",
                              "7 days from the day of administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The following information will be collected from the subjects during the follow-up visits or calls:\n\nMedical history review\nPhysical exam and vital signs\nAssessment for delayed adverse reactions",
                              "Survival of the subjects in the 2 arms of the study",
                              "COVID-19 polymerase chain reaction (PCR) test result as negative in the subjects in the 2 arms of the study"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to clinical improvement",
                              "Overall Survival",
                              "COVID-19 polymerase chain reaction (PCR) test result as negative"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months",
                              "3 months",
                              "3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05387278"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Ventilator-free days at 28days",
                              "Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "7 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The effect of MSC application at different times on mortality will be evaluated."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Effect on mortality after MSC administration in Groups I, II, III"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "7, 14 and 28 days after MSC application"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series",
                              "Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://pubmed.ncbi.nlm.nih.gov/33514427/",
                              "https://pubmed.ncbi.nlm.nih.gov/32811531/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05240430"
                        ]
                  },
                  {
                        "Rank": 19,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "All-cause mortality at 60 days and then annually",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the leucocyte Count (number/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the trombocyte Count (number/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of CRP (mg/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of PK (INR)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of creatinine (\u03bcmol/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of ASAT (\u03bckat/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of ALAT (\u03bckat/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in the plasma concentration of NT-proBNP (ng/L)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in blood pressure (mmHg)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in body temperature (\u00b0C)",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in pulmonary compliance (dynamic and static) until day 10 post-infusion",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in driving pressure (Plateau pressure- PEEP) until day 10 post-infusion",
                              "Changes from baseline (Day 1; prior to administration of ATIMP) in oxygenation (PaO2/FiO2) until day 10 post-infusion",
                              "Number of days with ventilator support",
                              "Changes in amount of pulmonary bilateral infiltrates assessed by pulmonary X-ray from baseline (Day 1; prior to administration of ATIMP) until day 60",
                              "Changes in Sequential Organ Failure Assessment (SOFA) score from baseline (Day 1; prior to administration of ATIMP) and during the ICU-period",
                              "Duration of ICU stay and hospital stay (number of days; whole hospital period + calculated from Day 1)",
                              "Recovery of lung function assessed by Spirometry (FEV1, Vital Capacity) at day 60 and then annually",
                              "To assess development of lung fibrosis using the HRCT Fibrosis Score using Computed tomography (CT) at baseline and on day 1, 3, 7, 10, end of ICU-residence, end of hospital stay, day 60, 6 month and 12 month and end of study (if possible during the infectious stage depending on hospital safety regimen during the pandemic).",
                              "Assessment of the patient's physical capacity by 6-Minute-Walk-Test (6MWT), starting at 6 months post Day 1 and then annually",
                              "Changes in Quality of Life by assessing the Short Form Health Survey (SF-36) score (starting at 6 months post Day 1 and then annually; patient reported outcome)",
                              "Change in blood biomarkers related to the proposed mechanisms of action of KI-MSC-PL-205 in ARDS",
                              "Sensitisation tests (test for donor-specific antibodies) against KI-MSC-PL-205 donor"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety; All-cause mortality",
                              "Changes in Leucocytes",
                              "Changes in Trombocytes",
                              "Changes in plasma concentration of C-reactive protein (CRP)",
                              "Changes in plasma concentration of Prothrombin complex (PK)",
                              "Changes in plasma concentration of Creatinine",
                              "Changes in plasma concentration of Aspartate amino transferase (ASAT)",
                              "Changes in plasma concentration of Alanine amino transferase (ALAT)",
                              "Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)",
                              "Changes in Blood pressure",
                              "Changes in Body temperature",
                              "Efficacy; Changes in pulmonary compliance",
                              "Efficacy; Changes in driving pressure (Plateau pressure- PEEP)",
                              "Efficacy; Changes in oxygenation (PaO2/FiO2)",
                              "Efficacy; Duration of ventilator support",
                              "Efficacy; Pulmonary bilateral infiltrates",
                              "Efficacy; Sequential Organ Failure Assessment (SOFA) score",
                              "Efficacy; Hospital stay",
                              "Lung function",
                              "Lung fibrosis",
                              "Six minutes walk test",
                              "Changes in Quality of life",
                              "Blood biomarkers",
                              "Sensitisation test"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60 days post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion",
                              "Baseline (pre-infusion),day 1, 2, 3, 4, 7, 10 and 60 post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, end of ICU",
                              "Day 60 post-infusion",
                              "Day 60 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 3, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 1, 2, 3, 4, 7 and 10 post-infusion, 6 months, 1, 2, 3, 4 and 5 years post-infusion",
                              "Baseline (pre-infusion), day 60 post-infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 20,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Quantify pulmonary respiratory function measured by chest computerized tomography",
                              "The efficacy of UC-MSC treatment was measured by arterial blood gas analysis",
                              "The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation\uff0cIL-6",
                              "The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation\uff0cIL-8"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Participants will be followed for the duration of hospital,2 day post-infusion, and days 7,14.",
                              "Participants will be followed for the duration of hospital,2 day post-infusion, and days 7,14.",
                              "6 hours post-infusion, and days 1, 2, and 3",
                              "6 hours post-infusion, and days 1, 2, and 3"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 21,
                        "ResultsFirstSubmitDate": [
                              "October 15, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "December 1, 2021"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "20200370"
                        ],
                        "SecondaryIdDomain": [
                              "Secondary Protocol ID"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Number of participants that are alive at 31 days post first infusion follow up corresponding to 28 day post second infusion.",
                              "Number of participants alive at 60 days post first infusion follow up.",
                              "Time to discharge or, if the subject was hospitalized, no longer requiring supplemental oxygen and no longer requiring COVID-19-related medical care by 31 days. The numbers represent days at which 25%, 50%, 75% subjects within the treatment group had recovered.",
                              "Number of days participants were off ventilators during 28 days post second infusion.",
                              "Number of days participants were off ventilators within up to 90 days of hospitalization.",
                              "Respiratory Rate-Oxygenation (ROX) index is defined as the ratio of oxygen saturation as measured by pulse oximetry (SpO2)/ Fraction of inspired oxygen (FiO2) to respiratory rate. This index can be used in the assessment of disease progression and the risk of intubation in COVID-19 patients with pneumonia.",
                              "Measure of the fraction of inspired oxygen (FiO2) and its usage within the body during intensive care, measured using fNIRS (Functional Near Infrared Spectroscopy). The calculation for Oxygenation index is ((FIO2 * Mean airway pressure)/partial pressure of oxygen).",
                              "Measuring the respiratory mechanics; positive end-expiratory pressure (PEEP) and plateau pressure (Pplat) in ventilated patients visit 8 (day 6)",
                              "Sequential Organ Failure Assessment (SOFA) Scores is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from a minimum of 0 (normal) to a maximum of 4 (high degree of dysfunction/failure). The total score corresponds to the sum of the six different scores of the organ systems. In total, the minimum SOFA score is 0 (normal) and the maximum SOFA score is 24 (highest degree dysfunction/failure).",
                              "SIT measures the participant's sense of smell. SIT has a total score ranging from 0 to 40 with the higher the score indicating a more normal sense of smell",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples.",
                              "Measures the total amount of the oxygen-carrying protein in the blood as assessed via serum blood samples.",
                              "The percentage by volume of red cells in your blood as assessed via serum blood samples.",
                              "the amount of immune cells (that is one of the first cell types to travel to the site of an infection) as assessed via serum blood samples",
                              "Lymphocyte count as assessed via serum blood samples",
                              "Glomerular filtration rate (GFR) as assessed via serum blood samples to check how well the kidneys are working. It estimates how much blood passes through the glomeruli each minute.",
                              "Total protein as assessed via serum blood samples as a part of the comprehensive metabolic panel (CMP). It is a measurement of the sum of albumin and globulins.",
                              "Sodium levels as assessed by serum blood samples.",
                              "Potassium levels as assessed via serum blood samples.",
                              "Creatinine levels as assessed via serum blood samples",
                              "Glucose levels as assessed via serum blood samples",
                              "Albumin levels as assessed via serum blood samples",
                              "Alkaline phosphatase levels as assessed via serum blood samples for the Comprehensive Metabolic Panel.",
                              "The alanine aminotransferase or serum glutamate-pyruvate transaminase (ALT or SGPT) test as assessed via serum blood samples",
                              "The aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST or SGOT) test as assessed via serum blood samples",
                              "Bilirubin levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Blood urea nitrogen (BUN) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Calcium levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Chloride levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Carbon Dioxide (CO2) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples on day 6 (visit 8).",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples.",
                              "Analysis of TNF\u03b1 in peripheral blood plasma",
                              "Analysis of TNF\u03b2 in peripheral blood plasma",
                              "Analysis of soluble tumor necrosis factor receptor 2 (sTNFR2) in peripheral blood plasma",
                              "Viral load as assessed in blood plasma for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) via Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 3 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 6 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 14 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants with positive, negative, or borderline SARS-CoV-2 Immunoglobulin M (IgM)/Immunoglobulin G (IgG) serology from serum blood samples."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Survival at 31 Days Post First Infusion",
                              "Survival at 60 Days Post First Infusion",
                              "Time to Recovery",
                              "Ventilator-Free Days Throughout 28 Days Post Second Infusion",
                              "Ventilator-Free Days Throughout 90 Days",
                              "Respiratory Rate and Oxygenation Index (ROX Index)",
                              "Oxygenation Index (OI)",
                              "Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)",
                              "Sequential Organ Failure Assessment (SOFA) Scores",
                              "Smell Identification Test (SIT) Scores",
                              "White Blood Cell Count (WBC)",
                              "Platelets Count",
                              "Hemogoblin",
                              "Hematocrit",
                              "Neutrophils",
                              "Lymphocytes",
                              "Glomerular Filtration Rate",
                              "Total Protein",
                              "Sodium",
                              "Potassium",
                              "Creatinine",
                              "Glucose",
                              "Albumin",
                              "Alkaline Phosphatase",
                              "Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)",
                              "Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)",
                              "Total Bilirubin",
                              "Blood Urea Nitrogen (BUN)",
                              "Calcium",
                              "Chloride",
                              "Carbon Dioxide (CO2)",
                              "C-Reactive Protein Levels",
                              "Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio",
                              "D-dimer Levels",
                              "25-Hydroxy Vitamin D Levels",
                              "Tumor Necrosis Factor-alpha (TNF\u03b1)",
                              "Tumor Necrosis Factor-beta (TNF\u03b2)",
                              "Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)",
                              "Viral Load by SARS-CoV-2 RT-PCR",
                              "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion",
                              "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion",
                              "Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion",
                              "Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "31 Days",
                              "60 days",
                              "31 days",
                              "28 days post second infusion",
                              "90 days or hospital discharge, whichever is earlier",
                              "day 6",
                              "day 6",
                              "day 6",
                              "Day 6",
                              "90 days",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "Day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 6",
                              "day 3 post first infusion",
                              "day 6",
                              "day 14",
                              "day 14 post first infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 22,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Correlate and analyze the Sequential Organ Failure Assessment (SOFA) score in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO\u2122, an interventional exosome therapy in COVID-19 patients. An increased SOFA score is predictive of increased mortality.",
                              "Berlin Score is a validated measure of Acute Respiratory Distress Syndrome diagnosis, which is common in COVID-19 patients, before and after receiving the interventional exosome therapy, ARDOXSO\u2122."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO\u2122 as an interventional exosome therapy.",
                              "Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "90 Days from last dose",
                              "90 Days from last dose"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04798716"
                        ]
                  },
                  {
                        "Rank": 23,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "SOFA score is a measure of organ failure",
                              "Crs is a physiological measure of pulmonary function in ARDS",
                              "P/F ratio is a physiological measure of pulmonary function in ARDS"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Oxygenation index",
                              "Sequential Organ Failure Assessment (SOFA) score",
                              "Respiratory compliance (Crs)",
                              "Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)",
                              "Driving Pressure",
                              "Extubation and reintubation",
                              "Ventilation free days at day 28",
                              "Length of ICU and hospital stay",
                              "28-day and 90-day mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Days 4 and 14",
                              "Days 4, 7 and 14",
                              "Days 4, 7 and 14",
                              "Days 4, 7 and 14",
                              "Days 4, 7 and 14",
                              "Up to day 14 or until the patient is discharged from ICU or the patient dies",
                              "Day 28",
                              "Until the patient is discharged or the patient dies",
                              "Up to 28 and 90 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03042143"
                        ]
                  },
                  {
                        "Rank": 24,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "All-cause mortality rate at Day 60 and 90",
                              "Number of ventilator-free days through Day 28",
                              "Number of ICU days through day 28",
                              "Change in clinical status as assessed using the WHO Clinical Progression Scale (0-10 scale, where lower score means a better outcome) at Day 28",
                              "Change in oxygenation as assessed using PaO2:FiO2 ratio"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "All-cause mortality rate at Day 60 and 90",
                              "Number of ventilator-free days through Day 28",
                              "Number of ICU days through Day 28",
                              "Change in clinical status",
                              "Change in oxygenation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline through Day 60 and Day 90",
                              "Baseline through Day 28",
                              "Baseline through Day 28",
                              "Baseline to Day 28",
                              "Baseline to Day 14 Day 28, and Day 60"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 25,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Lung mechanics includes arterial oxygen saturation, tidal volume, minute ventilation, and ratio of PaO2/FiO2.",
                              "Systolic, diastolic, and mean arterial blood pressure Amount of required vasopressor Heart rate",
                              "Death from any cause at 14 and 28 days after mesenchymal stem cell infusion",
                              "Interleukin (IL)-1, IL-6, IL-8, and IL-10",
                              "Lactate, DIC score, SOFA score, C-reactive protein, and procalcitonin",
                              "Failure of ventilator weaning, weaning time, ventilation time",
                              "Total duration of ICU stay and hospital stay"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Lung mechanics",
                              "Hemodynamic parameters",
                              "Mortality",
                              "Plasma cytokines",
                              "Markers for inflammation and infection",
                              "Ventilator weaning parameters",
                              "ICU and hospital stay"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at 3, 14, and 28 days after mesenchymal stem cell infusion",
                              "at 3, 14, and 28 days after mesenchymal stem cell infusion",
                              "at 14 and 28 days after mesenchymal stem cell infusion",
                              "at 3, 14, and 28 days after mesenchymal stem cell infusion",
                              "at 3, 14, and 28 days after mesenchymal stem cell infusion",
                              "at 3, 14, and 28 days after mesenchymal stem cell infusion",
                              "at 28 days after mesenchymal stem cell infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02112500"
                        ]
                  },
                  {
                        "Rank": 26,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The dose will be selected based on the assessment of dose-limiting toxicity and maximum tolerated dose.",
                              "The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care 7. Not hospitalized."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Selection of an appropriate dose of BX-U001 for the following Phase 2 study",
                              "All-cause mortality",
                              "Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.",
                              "Duration of ICU stay",
                              "Duration of hospital stay",
                              "Changes in blood cytokine levels"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 14",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 27,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "D-dimers blood levels",
                              "distribution of phenotypes of immune cells",
                              "Levels of specialized pro-resolving lipid mediators within alveolar macrophages and bronchoalveolar lavage",
                              "Cytokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions",
                              "Chemokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions",
                              "Survival at 10 days and 28 days",
                              "Time to removal of endotracheal tube",
                              "lymphocyte subpopulations in peripheral blood by flow cytometry prior and after MSC infusion (day 0,3,5,10)",
                              "evaluate SARS-CoV-2-specific antibody titers in the serum of patients prior and post MSC infusion.",
                              "evaluate levels of complement molecules (C5-C9) in the serum of patients prior and post MSC infusion"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "D-dimers",
                              "phenotype",
                              "pro-resolving lipid mediators",
                              "cytokines",
                              "chemokines",
                              "Survival",
                              "extubation",
                              "lymphocyte subpopulations",
                              "SARS-CoV-2-specific antibody titers",
                              "complement molecules (C5-C9)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "day 0, 1, 2, 3, 10 and 15",
                              "day 0, 1, 2, 3, 10 and 15",
                              "day 0, 1, 2, 3, 10 and 15",
                              "day 0, 1, 2, 3, 10 and 15",
                              "day 0, 1, 2, 3, 10 and 15",
                              "day 10 and 28",
                              "day 28",
                              "day 0, 3, 5 and 10",
                              "day 0, 5 and 10",
                              "day 0, 5 and 10"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 28,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of patients with treatment-emergent adverse events, by treatment group",
                              "Number of patients who, after the start of treatment, required rescue medication, by treatment group",
                              "Number of days that the patient requires invasive mechanical ventilation from the start of treatment to day +28, by treatment group",
                              "Days after treatment in which the patient remains alive and free of invasive mechanical ventilation, per treatment group.",
                              "Variation of the oxygenation index (PaO2 / FiO2) with respect to the baseline value, by treatment group.",
                              "Variation of the score of the Sequential Organ Failure Assessment (SOFA) Index with respect to the baseline value, by treatment group.",
                              "Variation of Acute Physiology and Chronic Health disease Classification System II (APACHE II) score, by treatment group.",
                              "Days of stay in the ICU from the day of admission until discharge to day 28, or date of death if earlier, by treatment group.",
                              "Variation in the count and percentage of leukocytes and neutrophils, by treatment group.",
                              "Feasibility will be evaluated by the time elapsed from the request of the treatment by the hospital center until the delivery date",
                              "Feasibility will be evaluated by the number of patients treated within 2 days of the request for treatment.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety of WJ-MSC",
                              "Need for treatment with rescue medication",
                              "Need and duration of mechanical ventilation",
                              "Ventilator free days",
                              "Evolution of PaO2 / FiO2 ratio",
                              "Evolution of the SOFA index",
                              "Evolution of the APACHE II score",
                              "Duration of hospitalization",
                              "Evolution of markers of immune response (leucocyte count, neutrophils)",
                              "Feasibility of WJ-MSC administration",
                              "Feasibility of WJ-MSC administration",
                              "Evolution of disease biomarker: polymerase chain reaction (RT-PCR)",
                              "Evolution of disease biomarker: lactate dehydrogenase (LDH)",
                              "Evolution of disease biomarker: D-dimer",
                              "Evolution of disease biomarker: Ferritin"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Bank of Catalonia",
                              "Hospital Cl\u00ednic de Barcelona",
                              "Hospital Vall d'Hebron",
                              "Hospital del Mar",
                              "M\u00fatua de Terrassa",
                              "Hospital de Bellvitge"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.bancsang.net",
                              "http://www.clinicbarcelona.org",
                              "http://www.vallhebron.com",
                              "http://www.parcdesalutmar.cat",
                              "http://www.mutuaterrassa.com",
                              "http://bellvitgehospital.cat"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 29,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "the length of ventilation and hospital stay",
                              "the length of ventilation and hospital stay",
                              "the length of ventilation and hospital stay",
                              "the length of ventilation and hospital stay"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "the days of ventialtion and hospital stay",
                              "the days of ventialtion and hospital stay",
                              "the days of ventialtion and hospital stay",
                              "the days of ventialtion and hospital stay"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 3",
                              "Day 7",
                              "Day 14",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 30,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The number of days from the first study treatment until return of oxygenation saturation (SpO2) \u2265 93% on room air (or PaO2/FiO2 \u2265 300 mmHg). If patient has chronic lung disease, recovery is defined as pre-COVID-19 SpO2 and O2 support.",
                              "Safety Endpoint",
                              "Efficacy Endpoint"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to Recovery",
                              "Incidence of Serious Adverse Events (SAE)",
                              "Number of Patients with All-cause Mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "61 days",
                              "61 days",
                              "61 days"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Direct Biologics, LLC"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://directbiologics.com/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  },
                  {
                        "Rank": 31,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Geometric mean titer",
                              "Change in overall assessment via Lung imaging via chest X-ray will be assessed and compared between baseline and 6 months",
                              "Change in overall assessment via Lung imaging via computerized tomography will be assessed and compared between baseline and 6 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Immunity",
                              "Change in Imaging via X-ray",
                              "Change in Imaging via Computerized Tomography"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to 6 Months",
                              "Baseline to 6 Months",
                              "Baseline to 6 Months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 32,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of participants with resolution and/or improvement of ARDS at 7 days, 14 days, 21 days, and 28 days according to the Berlin Criteria.\n\nChange in PF ratio from baseline to >200-300, and above >300\nAbsolute change in PF ratio"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Secondary Endpoint"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05491681"
                        ]
                  },
                  {
                        "Rank": 33,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "All-cause mortality rate at Day 60 and Day 90",
                              "Number of ventilator-free days through Day 28",
                              "Number of ICU days through Day 28",
                              "Change in clinical status as assessed using the 11-point WHO Clinical Progression Scale (0-10, where lower score means a better outcome)",
                              "Change in oxygenation as assessed using PaO2:FiO2 ratio"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "All-cause mortality rate at Day 60 and Day 90",
                              "Number of ventilator-free days through Day 28",
                              "Number of ICU days through Day 28",
                              "Change in clinical status",
                              "Change in oxygenation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline through Day 60 and Day 90",
                              "Baseline through Day 28",
                              "Baseline through Day 28",
                              "Baseline to Day 28",
                              "Baseline to Day 2, Day 4, Day 6, Day 14 and Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  },
                  {
                        "Rank": 34,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04524962"
                        ]
                  },
                  {
                        "Rank": 35,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "All-cause mortality at Days 60 and 90",
                              "Number of ventilator-free days through Day 28",
                              "Improvement in oxygenation at Day 2, 4, 6, 14, and 28 compared to Baseline, as assessed by PaO2/FiO2",
                              "SOFA score at Day 28 compared to Baseline"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Mortality at Days 60 and 90",
                              "Number of ventilator-free days",
                              "Improvement in oxygenation",
                              "SOFA score at Day 28"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Randomization through Day 60 and Day 90",
                              "Randomization through Day 28",
                              "Randomization to Day 2, Day 4, Day 6, Day 14, Day 28",
                              "Randomization to Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 36,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in serum inflammatory marker levels including Interleukin (IL) IL-6, IL-2, Tumor Necrosis Factor Alpha (TNF-a) and procalcitonin will be evaluated in ng/L.",
                              "Change in serum systemic inflammatory marker levels including D-dimer, high sensitivity C-reactive protein (hsCRP) and ferritin will be evaluated in mg/L.",
                              "Assessed using blood samples or nose/throat swabs.",
                              "Sequential Organ Failure Assessment (SOFA) will be used to assess organ failure including the cardiovascular system, coagulation system, liver, kidney and other extra-pulmonary organs. SOFA score ranges from 0-24 with the higher score indicating worse outcomes.",
                              "Sodium, Potassium, Chloride and Carbon Dioxide (CO2) will be evaluated in mmol/L. Changes from baseline to Day 30 will be compared between groups.",
                              "Serum Lactate Dehydrogenase (LDH) levels assessed in U/L. Changes in LDH from baseline to Day 30 will be compared between groups.",
                              "ICU monitoring status will be reported as the number of subjects discharged from the ICU within 7 days.",
                              "Percentage of participants requiring less use of vasoactive agents will be reported.",
                              "Percentage of participant deaths throughout the study period.",
                              "The percentage of participants with changes in serum immune marker levels including Cluster of Differentiation (CD) CD 4+ and CD 8+, as evaluated by treating physician will be reported.",
                              "Percentage of participants with changes in their chest imaging such as ground-glass opacity, local patch shadowing, bilateral patch shadowing and interstitial abnormalities will be reported. Imaging will be assessed by treating physician using chest radiography or chest Computed Tomography (CT).",
                              "Percentage of participants showing less pneumonia symptoms will be reported as evaluated by treating physician using chest radiography or chest CT."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in inflammatory marker levels",
                              "Change in systemic inflammatory marker levels",
                              "COVID-19 Viral Load",
                              "Change in SOFA score",
                              "Change in electrolytes levels",
                              "Change in LDH levels",
                              "Number of subjects discharged from the ICU",
                              "Percentage of participants with less requirement for vasoactive agents",
                              "Rate of Mortality",
                              "Percentage of participants with changes in immune marker expression",
                              "Percentage of participants with changes in radiologic findings",
                              "Percentage of participants with less pneumonia symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, Day 30",
                              "Baseline, Day 30",
                              "Up to 30 Days",
                              "Baseline, Up to 30 Days",
                              "Baseline, Up to 30 Days",
                              "Baseline, Up to 30 Days",
                              "Up to 7 Days",
                              "Up to 30 Days",
                              "Up to 30 Days",
                              "Up to 30 Days",
                              "Up to 30 Days",
                              "Up to 30 Days"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute at the University of Miami Miller School website"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 37,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04713878"
                        ]
                  },
                  {
                        "Rank": 38,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 39,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of days alive off mechanical ventilatory support calculated as the number of days, within the 60 days window, that patients were alive and free of mechanical ventilatory support.",
                              "Safety analyses will be assessed by adverse event rates calculated as the ratio of the total number of events over 30 days divided by total patient-time at risk for the specific event from randomization.",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 7",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 14",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 21",
                              "The number and percent of patients with resolution and/or improvement of ARDS at day 30",
                              "severity of ARDS according to Berlin Criteria at days 7 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "severity of ARDS according to Berlin Criteria at days 14 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "severity of ARDS according to Berlin Criteria at days 21 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "severity of ARDS according to Berlin Criteria at days 30 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.",
                              "Hospital length of stay",
                              "number of readmission",
                              "Change from baseline in Clinical Improvement Scale at day 7. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Change from baseline in Clinical Improvement Scale at day 14. Full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Change from baseline in Clinical Improvement Scale at day 21. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Change from baseline in Clinical Improvement Scale at day 30. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.",
                              "Changes from baseline in plasma hs-CRP concentration at days 7",
                              "Changes from baseline in plasma hs-CRP concentration at days 14",
                              "Changes from baseline in plasma hs-CRP concentration at days 21",
                              "Changes from baseline in serum hs-CRP concentration at days 30",
                              "Changes from baseline in IL-6 inflammatory marker level at 7 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 14 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 21 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 30 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 7 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 21 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 14 days",
                              "Changes from baseline in IL-6 inflammatory marker level at 30 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 7 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 14 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 21 days",
                              "Changes from baseline in TNF-alpha inflammatory marker level at 30 days",
                              "including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization",
                              "including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of days alive off mechanical ventilatory support",
                              "Number of adverse events",
                              "Number of participants alive at day 7",
                              "Number of participants alive at day 14",
                              "Number of participants alive at day 60",
                              "Number of participants alive at day 90",
                              "Number of participants alive at 12 Months",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Number of participants with resolution and/or improvement of ARDS",
                              "Severity of ARDS",
                              "Severity of ARDS",
                              "Severity of ARDS",
                              "Severity of ARDS",
                              "Length of stay",
                              "Readmissions",
                              "Length of Stay in Intensive Care Unit",
                              "Clinical Improvement Scale",
                              "Clinical Improvement Scale",
                              "Clinical Improvement Scale",
                              "Clinical Improvement Scale",
                              "Change in plasma hs-CRP concentration",
                              "Change in plasma hs-CRP concentration",
                              "Change in plasma hs-CRP concentration",
                              "Change in serum hs-CRP concentration",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-6 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in IL-8 inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Change in TNF-alpha inflammatory marker level",
                              "Pulmonary symptoms",
                              "Pulmonary symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60 days",
                              "30 days",
                              "7 days",
                              "14 days",
                              "60 days",
                              "90 days",
                              "12 Months",
                              "7 days",
                              "14 days",
                              "21 days",
                              "30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "12 months",
                              "12 months",
                              "12 months",
                              "7 days",
                              "14 days",
                              "21 days",
                              "30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "baseline and 7 days",
                              "baseline and 21 days",
                              "baseline and 14 days",
                              "baseline and 30 days",
                              "baseline and 7 days",
                              "baseline and 14 days",
                              "baseline and 21 days",
                              "baseline and 30 days",
                              "6 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 40,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Infection biomarker. Serum CRP levels can be used for early diagnosis of pneumonia, patients with severe pneumonia had high CRP levels.",
                              "CT assessment of pulmonary lesions and lung tissue changes",
                              "Indirect response to lung function",
                              "Degree of infection"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of \u0421-reactive protein (CRP, mg/L)",
                              "Evaluation of Pneumonia Improvement",
                              "Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)",
                              "Peripheral blood count recovery time"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8",
                              "At baseline, Day 1, Week 1, Week 2, Week 4, Week 8"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 41,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2020-001287-28"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Lung injury score",
                              "Oxygenation index",
                              "In-hospital mortality",
                              "Mortality",
                              "Ventilator-free days",
                              "Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)",
                              "Cumulative use of sedatives",
                              "Cumulative duration of use of sedatives",
                              "Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)",
                              "Cumulative use of neuromuscular blocking agents (other than used for intubation)",
                              "ICU-acquired weakness and delirium",
                              "Treatment-induced toxicity rate and adverse events up to day 28",
                              "Quality of life at one year (EQ5D-3L quality of life questionnaire)",
                              "Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level",
                              "Anti-HLA antibodies plasmatic dosage"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "At day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "At 6 months and 12 months",
                              "At day 1, 3, 5, 7 and 14",
                              "From baseline to day 14, and at 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 42,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 43,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 44,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Times to transitions between levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS",
                              "Changes in SpO2/FiO2 ratio or pAO2/FiO2 ratio compared to baseline, measured daily at a minimum; oxygenation index daily when on ventilator",
                              "Number of ventilator-free days (VFD) in period of 1 month from study treatment",
                              "Changes in CBC with differential from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment",
                              "Changes in blood glucose (mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment",
                              "Changes in levels of sodium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment",
                              "Changes in levels of potassium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment",
                              "Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment",
                              "Changes in levels of alanine transaminase (ALT; U/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment",
                              "Change in Urinalysis (UA) at baseline and 1 month after study treatment to assess for presence and qualitative proteinuria"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS",
                              "Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio",
                              "Number of ventilator-free days (VFD)",
                              "Changes in Complete Blood Count (CBC) with differential from baseline",
                              "Changes in levels of blood glucose (mg/dL) from baseline",
                              "Changes in levels of sodium (mEq/L) from baseline",
                              "Changes in levels of potassium (mEq/L) from baseline",
                              "Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline",
                              "Changes in levels of alanine transaminase (ALT; U/L) from baseline",
                              "Change in Urinalysis (UA) from baseline"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 month",
                              "1 month",
                              "1 month",
                              "1 month, 2 months, 3 months, 6 months, and 12 months",
                              "1 month, 2 months, 3 months, 6 months, and 12 months",
                              "1 month, 2 months, 3 months, 6 months, and 12 months",
                              "1 month, 2 months, 3 months, 6 months, and 12 months",
                              "1 month, 2 months, 3 months, 6 months, and 12 months",
                              "1 month, 2 months, 3 months, 6 months, and 12 months",
                              "1 month"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04494386"
                        ]
                  },
                  {
                        "Rank": 45,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Cytokines level",
                              "Immunological status",
                              "Improvement of pulmonary function",
                              "Infection biomarkers"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Detection of TNF-\u03b1 levels, IL-10 levels",
                              "Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).",
                              "Changes of oxygenation index (PaO2/FiO2) ,blood gas test",
                              "Changes of c-reactive protein and calcitonin"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1,3,6,12months",
                              "1,3,6,12months",
                              "1,3,6months",
                              "1,3,6,12months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04371601"
                        ]
                  },
                  {
                        "Rank": 46,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessment of safety",
                              "Circulating biomarker of inflammation",
                              "Not hospitalised, with resumption of normal activities = 1; Not hospitalised, but unable to resume normal activities = 2; Hospitalised, not requiring supplemental oxygen = 3; Hospitalised, requiring supplemental oxygen = 4; Hospitalised, requiring humidified nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both = 5; Hospitalised, requiring invasive mechanical ventilation, extracorporeal membrane oxygenation or both = 6; Death = 7",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Number of days from the time of initiating unassisted breathing to D28, assuming survival for at least 48 hours after initiating unassisted breathing and continued unassisted breathing to D28",
                              "Quality of life assessment",
                              "Disability assessment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence and severity of treatment-emergent adverse events",
                              "Change in C-reactive protein (CRP) levels",
                              "Proportional differences between groups on the Clinical Improvement Scale",
                              "Changes in P/F ratio",
                              "Changes in respiratory rate",
                              "Changes in oxygenation index",
                              "Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)",
                              "Changes in positive end-expiratory pressure",
                              "Ventilator-free days",
                              "Proportional differences between groups on the SF-36",
                              "Proportional differences between groups on the mini mental state examination"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "7 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04537351"
                        ]
                  },
                  {
                        "Rank": 47,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02985346"
                        ]
                  },
                  {
                        "Rank": 48,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To show how fetal blood transfusion (cord blood ) improve the morbidity of COVID 19 patient ( ICU days, M.V days ,oxygenation and perfusion parameters )"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "To evaluate the effect of increasing fetal hemoglobin protocol on the morbidity of patients with fulminant COVID-19"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "allove 5 months . 10 days for each group ."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05092724"
                        ]
                  },
                  {
                        "Rank": 49,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of Participants alive by Day 28",
                              "Number of Participants with ventilator-free Days by Day 28"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of Participants alive by Day 28",
                              "Number of Participants with ventilator-free Days by Day 28"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 50,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 51,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "MT2020-12"
                        ],
                        "SecondaryIdDomain": [
                              "University of Minnesota Masonic Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Acute Lung Injury Score is a composite 4 point scoring system validated by the NHLBI ARDS Network that considers PaO2/FiO2, the level of positive end-expiratory airway pressure, respiratory compliance, and the extent of pulmonary infiltrates on the chest radiograph"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of a reduction in one or more biomarkers of inflammation by day 7",
                              "Trend changes in PaO2:FiO2 ratio",
                              "Trend changes in Mean Airway Pressure",
                              "Trend changes in peak pressure",
                              "Trend changes in plateau pressure",
                              "Trend changes in Positive end-expiratory airway pressure (PEEP)",
                              "Incidence of mortality",
                              "Incidence of mortality",
                              "Number of ICU-free days",
                              "Number of days alive and ventilator free composite score 3",
                              "Change in acute lung injury (ALI) score 2",
                              "Incidence of serious adverse events",
                              "Number of days alive off supplemental oxygen"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 7 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "On the day of screening (baseline) and on days 3, 7 and 14 after first infusion",
                              "On the day of screening and on days 3, 7 and 14 after first infusion",
                              "28 days after first infusion",
                              "100 days after first infusion",
                              "28 days after first infusion",
                              "28 days after first infusion",
                              "Baseline and Day 28 after first infusion",
                              "28 days after first infusion",
                              "100 days after first infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 52,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [
                              "20710046"
                        ],
                        "RetractionSource": [
                              "de la Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC. Cancer Res. 2010 Aug 15;70(16):6682"
                        ],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 53,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measure and compare time to clinical recovery and clinical discharge compare to placebo.",
                              "Concentration of SpO2 by Pulse oximetry device during procedures and compare to placebo.",
                              "Chest imaging changes for 30 days compared to placebo. Information on the percent of damaged lungs will be analyzed and reported.",
                              "C-reactive protein (CRP, mg/L) concentration in the plasma will be measured. The result will be analyzed and compared in time.",
                              "Procalcitonin concentration in plasma (ng/mL) will be measured. The result will be analyzed and compared in time.",
                              "Ferritin concentration in plasma (ng/mL) will be measured. The result will be analyzed and compared in time.",
                              "Creatinine concentration (umol/L) in plasma will be measured. The result will be analyzed and compared in time.",
                              "Urea concentration (mmol/L) in plasma will be measured. The result will be analyzed and compared in time."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to clinical recovery (TTCR)",
                              "SpO2 concentration changes",
                              "Chest Imaging Changes",
                              "Blood biochemistry (CRP)",
                              "Procalcitonin concentration",
                              "Ferritin concentration",
                              "Creatinine concentration",
                              "Urea concentration"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 2 months",
                              "up to 2 months",
                              "Three times. At diagnosis, 10-14 days after treatment and 30 days after clinic discharge",
                              "Baseline, day 5, 10, 20",
                              "Baseline, day 5, 10, 20",
                              "Baseline, day 5, 10, 20",
                              "Baseline, day 5, 10, 20",
                              "Baseline, day 5, 10, 20"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04602442"
                        ]
                  },
                  {
                        "Rank": 54,
                        "ResultsFirstSubmitDate": [
                              "October 21, 2020"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "October 28, 2020"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measure and compare time to clinical recovery compared to placebo. Time to clinical recovery calculated by the number of days the patient has hospitalized.",
                              "The concentration of SpO2 by Pulse oximetry device during procedures in the groups. The measure was done before and after each inhalation (total 4 measures per day). The intraday SpO2 data of all patients in groups was calculated as Median with Inter-Quartile Range and presented in the table by days.",
                              "Blood biochemistry C reactive protein level in serum.",
                              "Lactic Acid Dehydrogenase (LDH) level in serum"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to Clinical Recovery (TTCR)",
                              "SpO2 Concentration",
                              "C-reactive Protein",
                              "Lactic Acid Dehydrogenase (LDH)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "from first inhalation until discharge from the clinic, up to 30 days",
                              "10 days during inhalation",
                              "At the begining of inhalation (day 1) and on next day of last inhalation (day 11)",
                              "At the beginning of inhalation (day 1) and on next day of last inhalation (day 11)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04491240"
                        ]
                  },
                  {
                        "Rank": 55,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Days of respirator treatment",
                              "Improvement of clinical symptoms including duration of fever and respiratory need",
                              "Mortality",
                              "Marker of Immunological function -CD4+ and CD8+ T cell count",
                              "C-reactive protein and leucocyte",
                              "Cytokine profile",
                              "Glomerular Filtration Rate",
                              "Duration of hospitalization"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 56,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Time to recovery, defined as discharge from the hospital (alive) or remaining in the hospital without the need for supplemental oxygen or other COVID-related medical care.",
                              "Increase in PaO2/FiO2 ratio by 50% by Day 4 (96 hours after first infusion). PaO2/FiO2 may be calculated from an arterial blood gas or imputed from the SpO2/FiO2 table",
                              "The number of days from hospitalization to discharge to home",
                              "The number of ventilator free days",
                              "Number of days requiring oxygen support",
                              "Percent of screened patients who are enrolled and randomized"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to recovery",
                              "Increase in PaO2/FiO2 ratio",
                              "Days to hospital discharge to home",
                              "The number of ventilator free days",
                              "Number of days requiring oxygen support",
                              "Percent of screened patients who are enrolled and randomized"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "4 days after MSCs",
                              "90 days",
                              "90 days",
                              "7 days",
                              "90 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  }
            ]
      }
}